BioXcel Therapeutics reports Q2 EPS ($2.45), consensus ($1.56)

Reports Q2 revenue $120,000, consensus $212,500. “We are incredibly excited about the upcoming top-line data readout for our SERENITY At-Home Phase 3 trial – our primary market research and preliminary results regarding the frequency of agitation episodes during the trial suggest a target addressable market meaningfully larger than our original estimate of 23 million agitation episodes in the at-home setting annually,” said Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics (BTAI). “This expanded opportunity estimate presents a significant prospect to help many bipolar disorder and schizophrenia patients, fulfilling our core mission.”